Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid Leukemia

Ítems similars

• Healthcare costs and utilization for patients age 50-64 years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogeneic hematopoietic cell transplantation
  per: Preussler, Jaime M., et al.
  Publicat: (2017)
• Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States 2004–2014: A Generalized Additive Modeling Approach
  per: Mau, Lih-Wen, et al.
  Publicat: (2020)
• Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities
  per: Preussler, Jaime M., et al.
  Publicat: (2016)
• Pre-Enrollment Reimbursement Patterns of Medicare Beneficiaries Enrolled in “At-Risk” HMOs
  per: Eggers, Paul W., et al.
  Publicat: (1982)
• Variation in Practice Patterns and Reimbursements Between Female and Male Urologists for Medicare Beneficiaries
  per: Nam, Catherine S., et al.
  Publicat: (2019)